Research
Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations
The Brief
- ZZ-FIRST is a prospective, multicenter, randomized phase 2 clinical trial led by the Vall d'Hebron Institute of Oncology's Prostate Cancer Group.
- The trial evaluated enzalutamide, an androgen receptor pathway inhibitor (ARPI), combined with a poly(ADP-ribose) polymerase inhibitor (PARPi).
- For tumors lacking targetable mutations, the combination added toxicity without a clear benefit.
Why it matters
It is a randomized trial result indicating that adding a PARP inhibitor to enzalutamide does not clearly help patients whose tumors lack targetable mutations, while increasing side effects.
Who’s affected
- prostate cancer researchers and clinicians
- patients with prostate cancer and their care teams
- #prostate cancer
- #clinical trial
- #enzalutamide
- #parp inhibitor
- #toxicity
The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi)…